Roche Bolsters India Partnering With Cipla, Entero To Handle Nephrology
Roche is pressing ahead with partnering deals in India as part of efforts to expand access to certain key existing brands and signals intent to continue to explore more collaborations wherever it needs to “reach out to more patients urgently.”
You may also be interested in...
Glenmark has dropped the price of its trastuzumab biosimilar by over 70% in India. Scrip talks to experts on what that may mean for the competition and also spotlights action around other HER2-directed therapies, including the impending arrival of blockbuster ADC Enhertu.
Most roads led to India in 2020 when it came to deals to expand access to COVID-19 therapies, but the challenging year also saw significant private equity interest and there are expectations of more action ahead in the new year.
Cipla’s generic of Merck & Co’s Proventil makes significant inroads in the US, with the Indian company confident that it has both a strong cost position and large capacity to take on competition. Pricing in the segment currently remains ‘respectable.’